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Abstract
Background: Cerebral malaria carries an unacceptable case fatality rate in children despite timely
and adequate chemotherapy. To improve the survival rate, adjunctive therapies previously tested
mainly focused on the modulation of the inflammatory response, without definitive effect in
humans. In this context, a new adjunctive strategy using a neuroprotective drug: erythropoietin
(epoietin-beta, Epo) was proposed.
Methods: An open-labelled study including cerebral malaria children (Blantyre coma score below
3) was conducted in Mali. The objective was to assess the short-term safety (seven days) of
erythropoietin at high doses (1,500 U/kg/day during three days) combined to quinine.
Results: 35 patients with unrousable coma were included in the study. None of expected side
effects of erythropoietin were observed during the seven days follow-up. No significant increase in
the case fatality rate (7/35 patients) was observed compared to other studies with mortality rates
ranging from 16 to 22% in similar endemic areas.
Conclusion: These data provide the first evidence of the short-term safety of erythropoietin at
high doses combined to quinine. A multicentre study is needed to assess the potential of Epo as an
adjunctive therapy to increase the survival during cerebral malaria.
Clinical registration number: ClinicalTrials.gov ID: NCT00697164
Background
Malaria is one of the most common life-threatening dis-
eases in sub-Sahara Africa with a dramatic impact on pub-
lic health: more than one million deaths each year.
Cerebral malaria (CM) carries unacceptable case fatality
rate in children despite timely and adequate chemother-
apy. The SEAQUAMAT group provided the first evidence
of artesunate superiority (mortality rate: 15%) compared
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malaria in adults [1]. However, available artemisinin-
based combination therapy (ACT) is not associated with a
complete recovery in case of severe malaria, suggesting a
potential role for adjunctive therapies in the early phase of
the disease. Most adjunctive therapies tested in human
cerebral malaria were focussed on the modulation of the
inflammatory response [2]. However, none of the trial
using adjunctive therapies from data obtained in animal
models provides an increase in survival or an improve-
ment of patient outcome [3-5]. It was highlighted that
most of these studies were underpowered [6]. In some
cases, these adjunctive drugs were responsible for deleteri-
ous effects and trials were suspended [7]. A new opportu-
nity was opened when the beneficial effect of neuro-
protective drugs, including erythropoietin (epoietin-beta,
Epo), was demonstrated both in animals [8,9] and
humans during stroke [10]. The neuro-protective effect is
mediated through the inhibition of cell death in the
ischemic penumbra surroundings the tissue injury [11].
There is now a growing evidence for this concept of cell
protection during acute ischemic diseases [12,13].
Epo has recently been considered in a new light as a tissue-
protective cytokine. Its neuro-protective properties have
attracted considerable attention: Epo and its receptor
(EpoR) are part of a highly potent endogenous neuro-pro-
tective system in the brain [14]. Similar to the mechanism
of action shown for cells in the haematopoietic system,
Epo acts on cells of the nervous system via binding to its
specific receptor EpoR. Dimerizing of EpoR leads to auto-
phosphorylation of the receptor associated Janus tyrosine
kinase 2 and activation of distal signal transduction cas-
cade: phosphatidylinositol-3-kinase (PI3-K), akt protein
kinase, RAS mitogen-activated protein kinases, signal
transducers and activators of transcription-5 (STAT-5) and
NF-kB-dependant transcription [15]. The underlying
mechanisms are hypothesized to be multifactorial. Epo
may antagonize the cytotoxic effect of glutamate, increase
expression of antioxidant enzymes, reduce nitric oxide
mediated formation of radicals, normalize cerebral blood
flow, influence neurotransmitter release and promote
neuroangiogenesis [16]. All these mechanisms are con-
tributing to attenuation of apoptosis [8,9] and reduction
of brain inflammation [9].
The effect of neuro-protective therapies was not previ-
ously investigated during malaria in humans, although
the manifestations of cerebral malaria partly share fea-
tures with neurological stroke, neuron damage related to
ischaemia-reperfusion stress or acute non-specific neuro-
logical disorders. From experimental malaria, it was spec-
ulated that the progression from cerebral malaria to death
could be counteracted by Epo high doses at the onset of
clinical phase of the disease [17].
While the safety of Epo in chronic diseases is known,
using high doses for a short period of time is a major issue
to be addressed in severe cerebral malaria patients.
Indeed, in September 2008, FDA has been made aware of
preliminary safety concerns from a clinical trial conducted
in Germany investigating the use of epoietin-alfa high
doses (40,000 units daily for three days) to treat acute
ischemic stroke, while investigators considered this as pre-
mature alert. Early in 2009 another clinical trial using
epoietin-alfa high doses (1,000 unit/kg/day for seven
days) in extremely premature infants to prevent/attenuate
brain injury was also FDA hold. In both cases, epoeitin-
alfa was used and FDA did not communicate their final
conclusions and recommendations to the public. The in
vivo/in vitro bioactivity ratio is more than 20% higher for
epoietin-beta than for epoietin-alpha, because epoietin-
beta is less sialylated than epoietin-alpha [18,19]. Desia-
lylation of Epo is known to reduce the plasma survival of
Epo and the biological effect and to increase the affinity of
Epo for its receptors. To obtain the appearance of exoge-
nous Epo in the cerebrospinal fluid and the neuro-protec-
tive effect, Epo doses higher than those used for anaemia
treatment are needed [20].
To document the safety of epoietin-beta high doses (1500
U/Kg) at day 7 post-admission, combined to quinine, the
local recommended drug for cerebral malaria, a clinical
trial in Bamako (Mali) including children admitted with
highly critical stage cerebral malaria (Blantyre coma score
<3) was conducted. The safety was defined as the lack of
severe adverse effects attributable to Epo.
Methods
Study design
This was an open-labelled study conducted in Gabriel
Toure Hospital, one of the national referral hospitals of
Bamako, Mali. Ethical approval was obtained from the
Institutional Review Board (IRB) of the Faculty of Medi-
cine, Pharmacy and Dentistry of Bamako, and from the
board of trustees of Roche Foundation for Anaemia
Research (RoFAR). The trial was registered
(NCT00697164, clinicaltrials.gov). The funders had no
role in the study design, data collection, analysis, decision
to publish or preparation of the manuscript. Written
informed consent was obtained from parents or legal
guardians of patients prior to enrolment.
Children between six months and 14 years old, presenting
cerebral malaria with a Blantyre coma score <3 due to
Plasmodium falciparum infection (confirmed by blood
thick smears microscopical examination), were included
in the study after consent obtained from parents or legal
guardians. All other categories of severe malaria, includ-
ing severe anaemia (defined by haemoglobin levels below
5 g/dL), respiratory distress and acute renal failure werePage 2 of 8
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lepsy, cerebral palsy), known sickle cell disease and inter-
current infections were excluded.
Cerebral malaria patients received anti-malarial treatment
according to the recommendation of Mali National
Malaria Control Programme. They received quinine intra-
venously 20 mg salt/kg bw on admission then 10 mg salt/
kg bw every eight hours from day 1 to day 3. Then, they
received artesunate-amodiaquine combination (4 mg/kg/
day and 10 mg/kg/day, respectively) from day 4 to day 6.
Adjunctive therapy was based on intravenous infusion of
1500 U/kg/day rHuEPO (epoietin-beta, Neorecormon®)
from admission to day 3 (three doses). Considering the
very low risk of side effects with a short-term rHuEPO
treatment, 35 patients were included, which is within the
range of a generally accepted sample size for this purpose.
The primary end point was survival of patients by day 7
post-admission. Due to the lack of follow-up information
after discharge from hospital, and to the impossibility for
patients to come back to outpatient clinic for economic
reasons, we could not ascertain the long-term outcome
patients who survived.
Secondary end points were i) incidence of adverse effects,
ii) incidence of abnormal laboratory values, iii) rate of
neurological disorders evaluated by clinical examination
and Blantyre coma score.
An independent local Medical Monitor and an external
Data and Safety Monitoring Committee, composed by
four members, were designed and evaluated adverse
events and other safety data. Reports of cases were regu-
larly sent to the data monitoring committee. The case cau-
salities were assessed using the standardized WHO-UMC
system by DSMC members. All the investigators com-
pleted IRB certificate for clinical trial and passed the eval-
uation from the Collaborative Institutional Training
Initiative (CITI, University of Miami and Fred Hutchinson
Cancer Research Center). The study adhered to the inter-
national conference on Harmonization Guidelines for
Good Clinical Practices and was conducted in accordance
with the Declaration of Helsinki.
Trial procedures
The following data were collected from all enrolees on a
standardized case report form. Demographic details (date
of birth or age, gender, weight, ethnic group, address), his-
tory of present illness (delay before admission, convul-
sions and coma prior to admission, date and time of
admission, anti-malarial treatment before admission),
physical and biological findings were gathered on admis-
sion and every day during the follow-up. Standard operat-
ing procedures were developed, applied to all patients and
were strictly respected. The clinical team was trained in
operating and maintaining the instruments. Biological
quality controls for all the biological parameters were per-
formed once a week. Biological abnormalities were dou-
ble-checked. Regular meetings were held to ensure that
data quality was maintained.
Clinical and biological monitoring was in agreement with
the WHO guidelines for cerebral malaria [21]. Tempera-
ture, Blantyre coma score, respiratory status, seizure,
blood pressure, cardiac frequency, jaundice, dehydrata-
tion were recorded on admission and every four hours
from day 1 to day 3, then every eight hours by the end-
point.
Parasitaemia (Giemsa-stained thick smears), haemo-
globin level (Hemocue Hb 201+®, Hemocue), blood satu-
ration (Fingertip 300D®, RDSM), blood lactate (Lactate
Pro®, FaCTCanada), blood gas analysis (pHOx Basic,
Novabiomedical), diuresis, haemoglobinuria (dipstick
urinalysis), were recorded daily. Blood glucose levels
(Accu-Check Go®, Roche diagnostic) were recorded every
eight hours for the first two days, then daily. Creatininae-
mia and alanine aminotransferase assays were referred to
local reference laboratory.
Continuing supportive care was provided according to
standard recommendation [21] and patient were treated
with the highest level of care available on site. However,
neither oxygen nor mechanical ventilation was available
in this paediatric emergency ward. Repetitive seizures
were treated by diazepam. Hypoglycaemia, anaemia and
acidosis were treated empirically.
Statistical analysis
This study was the first part of a wider-sized project aimed
to evaluate the proof-of-concept of epoietin-beta as
adjunctive therapy during cerebral malaria. At this step,
the study was designed to demonstrate the short-term
safety of Epo high doses in endemic area low-income
country with poor medical capabilities. The effects of
high-dose recombinant human epoietin-beta for 35 con-
secutive patients who have been admitted with a diagno-
sis of highly severe cerebral malaria were studied. Epo was
injected intravenously shortly after admission and subse-
quently during 2 days. Safety analysis was undertaken for
patients who were assigned to receive at least one dose of
study drug.
Two different people performed data entries. Database
discrepancies were visually checked against source docu-
ments and resolved by consensus. Assessment of demo-
graphics, clinical and laboratory variables were based on
descriptive statistics including mean, standard deviation,
medians, and proportions. Mean values of the vital sign
and biological parameters were compared using a Student
t-test for continuous variables with a normal distribution.Page 3 of 8
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test for categorical variables. P-values were based on two-
sided significant level of 5%.
Results
Baseline characteristics
Overall, 35 patients were included in the study between
October 2007 and September 2008. 28 patients received
full treatment including three doses of Epo at 1,500 UI/kg
combined with quinine and completed follow-up accord-
ing to the protocol. Seven patients died before the end of
the treatment and received only one or two doses of treat-
ment.
Table 1 shows baseline patients characteristics. At time of
admission, a similar number of patients presented a Blan-
tyre coma score of 1 (17 patients) and 2 (18 patients). The
population showed normally distributed ages with a
median of 6 years (range: 2–12). Most of the patients were
febrile (> 37.4°C) at admission except 7 (20%). No infor-
mation was available concerning the use of antipyretic
drugs self-medication. The mean duration of fever before
reference to the hospital was 75 ± 32 hours (range: 12–
148). Median parasitaemia value was 7,100 asexual blood
forms of mono-specific P. falciparum detected on thick
blood films, and PCR confirmed from paper blood spots.
All patients presented haemoglobin levels on admission
from 7.0 to 12.4 g/dL (median: 9.3 g/dL). None of the
patients presented severe hypoglycaemia except two, who
were treated before admission with a three-day course of
quinine (13 mg/kg/day) or high dose chloroquine (700
mg total dose) given by a primary health care officer.
Clinical outcomes
For the primary intention-to-treat analysis (35 patients),
there were no significant differences in demographic (Stu-
dent t-test) or disease characteristics (Fisher F-test)
between the surviving and the deceased patients (table 1).
Seven patients died during the early stages of the hospital-
ization (all before 48 hours after admission). The circum-
stances of these deaths were as followed:
Table 1: Baseline and disease characteristics in the included population







p-value surviving vs deceased
Baseline Characteristics: Mean ± standard deviation (range) Student t-test
Sex ratio (M/F) 1.7 (22/13) 2.1 (19/9) 0.75 (3/4)
Age, years 6.3 ± 2.5 (2–12) 6.2 ± 2.7 (2–12) 6.7 ± 2.4 (3–9) .60
Weight, kg 19.5 ± 6.9 (10–35) 19.7 ± 7.5 (10–35) 18.9 ± 6.0 (11–26) .62
Temperature,°C 38.6 ± 1.3 (36.2–40.6) 38.7 ± 1.4 (36.2–40.6) 37.8 ± 1.0 (36.6–39.6) .08
Clinic day 1: Patient ratio (%) Fisher F-test
Blantyre score = 1 17/35 (49%) 12/28 (43%) 5/7 (71%) .32
Blantyre score = 2 18/35 (51%) 16/28 (57%) 2/7 (29%)
≥ 1 seizure 23/35 (66%) 17/28 (61%) 6/7 (85%) .16
Deep breathing 7/35 (20%) 4/28 (14%) 3/7 (42%) .06
Haemoglobinuria 7/35 (20%) 6/28 (21%) 1/7 (14%) 1
Jaundice 4/35 (11%) 4/28 (14%) 0/7 (0%) .55
Biological values day 1 Mean ± standard deviation (range) Student t-test
SaO2, % 91.0 ± 8.7 (73–98) 89.8 ± 9.4 (73–98) 95.1 ± 3.5 (88.7–98) .10
asexual 43,000 ± 62,000 45,000 ± 46,000 37,000 ± 54,000 .85
P. falciparum/μL (200–250,000) (200–250,000) (625–140,000)
Blood pH 7.29 ± 0.1 (7.1–7.43) 7.3 ± 0.1 (7.2–7.4) 7.3 ± 0.2 (7.1–7.4) .72
Blood Lactates, mmol/L 6.0 ± 3.6 (1.4–15.4) 5.8 ± 3.3 (1.4–15.4) 6.3 ± 3.6 (2–11.7) .78
Haemoglobin, g/dL 9.4 ± 1.4 (7.0–12.4) 9.6 ± 1.4 (7.0–12.4) 9.0 ± 1.2 (7.1–10.3) .32
Plasma glucose, mmol/L 6.4 ± 3.6 (0.8–19.4) 6.3 ± 2.3 (1.1–11.3) 7.8 ± 6.1 (1.25–19.4) .54
Plasma creatinin, μmol/L 57 ± 28 (21–130) 58.4 ± 26.0 (29–130) 36.7 ± 14.8 (21–60) .02
ALAT, IU/L 87 ± 129 (7–600) 100 ± 150(7–600) 47 ± 18 (22–71) .11
Clinical and biological data were gathered at the time of admission. Included patients were stratified according to the primary end-point outcome 
(surviving or died patients on day six post admission). Student t-test or Fisher F-test were used to compare the two groups when appropriate.Page 4 of 8
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at admission with Epo, quinine, diazepam intramuscu-
larly and phenobarbital for repeated seizures, but without
parasite blood stage documentation. He was later classi-
fied as protocol violation. He died one hour after admis-
sion without aetiologic diagnosis.
- One child (3 years old, 11 kg) received a total dose of
700 mg of chloroquine the week before admission and
was admitted with a Blantyre score at 1, repeated seizures,
profound hypoglycaemia and respiratory pauses. He
received at admission quinine and Epo, plus 5 mg
diazepam and 40 mg phenobarbital, and died three hours
later.
- One child (7 years old, 20 kg) was admitted with
repeated seizures that were not terminated by initial injec-
tion of diazepam (10 mg) intramuscularly. He received
successively two more diazepam injections and 120 mg
phenobarbital during the first 30 hours, while he pre-
sented respiratory pauses. Mechanical ventilation and
oxygen were not available and the patient died 44 hours
post-admission after respiratory distress. He received two
doses of Epo.
- One child (4 years old, 13 kg) was admitted with a Blan-
tyre coma score of 2, with seizures and respiratory distress.
Clinical improvement was observed after two doses of
quinine and Epo. The children received enteral nutrition
prepared by his family without septic care at 20, 24 and 28
hours post-admission. He suddenly presented vomiting
during four hours, hypotension, mydriasis and respiratory
arrest at 32 hours post-admission. No bacterial culture
could be obtained during the time of the lethal shock due
to the lack of these facilities during the night.
- One child (8 years old, 21 kg) was admitted with deep
acidosis (blood pH = 7.1, controlled) not taken into
account by medical team until 24 hours when the blood
pH was measured at 7.0. He received Ringer 500 mL after
24 and 48 hours without biological and clinical improve-
ment and died after 51 hours.
- Two children (aged 7 & 9) died immediately and two
hours post-admission, respectively, the first deceased
child was nearly impossible to treat using intravenous
route due to severe hypotension and the second with high
blood lactate level (11.7 mmol/L). They received quinine
and Epo treatment at admission, but no resuscitation was
possible.
The five first of these deaths were classified by the DMC as
unlikely due to Epo according to the WHO-UMC system.
The others two children were classified as non-evaluable.
28/35 patients survived at day 7 post-admission (80%).
Although the study was not designed to detect a treatment
effect on the time to recovery, the Blantyre coma score
increased from stages 1–2 to stages 4–5 in less than 48
hours.
Short-term safety
Epo is a safe drug used for years to treat chronic anaemia
caused by renal failure or cancer. Here much higher doses
of that drug were used during a very short period of time.
Side effects suspected to be due to high doses were moni-
tored.
None of the known side effects of EPO including increase
in blood pressure [22], and venous thrombosis due to
excessive erythropoeisis, were observed during the 7 days
follow-up [23]. Among the surviving patients, no increase
of haemoglobin blood level was observed during the time
of Epo treatment, between admission (mean = 9.4 ± 1.4 g/
dL), day 3 (mean = 9.0 ± 2.5 g/dL) and day 7 (mean = 8.3
± 1.8 g/dL). The decrease in haemoglobin level between
the mean values at admission and day 3 was not signifi-
cant (Student t-test > 0.05), while it became significant at
day 7 (Student t-test = 0.03).
Discussion
Child mortality from malaria is still unacceptable in sub-
Saharan Africa, while ACT was deployed in many endemic
areas. These drugs are quite effective in clearing the blood
stage parasites within 48 to 72 hours [24]. Most deaths
occur within 24 hours of admission to hospital meaning
before anti-malarial drugs effect [25]. This well-known
observation provides a therapeutic window for adjunctive
therapies administration, particularly those targeted the
host cells protection. Adjunctive therapies have been
tested in humans but none clearly showed to be beneficial
[26]. Most of these trials were designed to block the down-
stream effects that occur as a result of P. falciparum infec-
tion or to resuscitate the patients using aggressive fluid
therapy [27]. More recently, the combination of erythro-
poietin high doses with artesunate showed a reduced
delay before clinical recovery and a 50% mortality
decrease in mice [28].
The haematopoietic growth factor Epo has been used as a
drug for the treatment of anaemia for almost two decades.
Since Epo and Epo-Receptor are expressed in several
organs (including kidney, brain, heart, muscle, endothe-
lial cells), Epo function is not limited to the haematopoi-
etic system [29]. Systemic administration of exogenous
Epo regulates cerebral blood flow, protects endothelial
cells against oxydative stress and reduces inflammation by
inhibiting pro-inflammatory cytokines [30]. These effects
are partly due to the inhibition of cell apoptosis and could
explain the tissue protective potential of Epo [31]. EpoPage 5 of 8
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shown to be well tolerated and associated with an
improvement in clinical outcome after one month [10].
Epo exhibits its high non-specific potential in various
other pathological conditions including renal failure and
schizophrenia [31].
Since the pathological mechanisms involved in ischaemia
share features with cerebral malaria, and none of the anti-
malarial drug is effective to control the progression of the
disease in the first hours of treatment, there was an oppor-
tunity for the use of Epo as an adjunctive therapy in the
early stage of cerebral malaria [32].
Children (median age: 6) referred to hospital after up to 6
days of fever were included. These children were living in
urban or peri-urban settings with mesoendemic transmis-
sion level. The overall sex ratio was 1.7 (male/female)
compared to 0.75 (3 males/4 females) for patients who
died at hospital.
Most of the patients received incomplete treatment (anti-
malarial drugs locally available) in primary health care
centres and were referred to hospital in the absence of
clinical improvement, leading to the late stages of unrous-
able coma observed at admission. Among the patients
included, there was a similar number of patients showing
a Blantyre coma score of 1 and 2 (17 and 18 respectively).
The aim of this study was to investigate the safety of Epo
during cerebral malaria. Patients suspected to present res-
piratory distress or renal failure before admission could
lead to a bias in the interpretation of the results. While
severe malaria is often a combination of severe anaemia
and cerebral malaria, patients with a significant decrease
in haemoglobin levels were not included to avoid any
interference in the data analysis with the potential effect
of Epo on erythropoiesis. However, it has to be remem-
bered that authors [10] demonstrated in a pilot study that
3 days of Epo at high doses did not increase haemoglobin
to levels exceeding the normal range, excluding the need
to use non-haematopoietic Epo derivatives such as car-
bamylated erythropoietin in that condition. This was con-
firmed here since a significant decrease in haemoglobin
level was observed at day 7, as expected during anti-malar-
ial treatment. Considering the low level of haemoglobin
in these children at discharge (mean = 8.3 ± 1.8 g/dL),
very common in endemic areas, it could be speculated
that a delayed increase in erythropoiesis will not lead to
abnormal or pathological red blood cells mass. None of
the patients showed blood mass increase, vascular throm-
bosis or hypertension along the 7 days follow-up. Among
the patients who survived, the neurological clinical
improvement was observed as expected in the first two
days of treatment.
Seven patients/35 died during the trial. Five were classi-
fied as unlikely due to Epo high doses by the DSMC and
none of these deaths should be attributed to Epo. Among
them, two patients received only one Epo dose and were
admitted with extremely severe symptoms and deep
coma. In the emergency situation, patients admitted with
low grade coma score were included and received Epo
treatment. Some patients were included despite the pres-
ence of respiratory distress. Nevertheless, it was decided to
present these information in intention-to-treat protocol
to avoid any bias in data analysis.
It is well recognize that good supportive care and manage-
ment of complications are essential in the treatment of
severe malaria [6]. Paediatric resuscitation presents a great
challenge for health workers who are faced with inade-
quate facilities and often advanced disease in children.
Deficiency in breath arrest management is one of the
major factors that could influence the outcome of the
resuscitation. Survival also depends on underlying dis-
eases and the time elapsing between arrest and the initia-
tion of the resuscitation. Broader provision of ventilation
facilities and early identification of cases that need intuba-
tion and ventilation may improve the prognosis of cardi-
opulmonary arrest. However, in many, if not mostly
paediatric wards in endemic areas hospitals, staffing lev-
els, clinical supplies and laboratory capacities are limited
[33]. The key question is whether clinical studies con-
ducted in resource-poor settings could help to improve
the therapeutic management of patients with cerebral
malaria, or to enhance only the capacity of local team
involved in these studies. Here, it could be speculated that
the capacity building needed to conduct this trial was nec-
essary and sufficient to demonstrate the safety of Epo high
doses in the resuscitation of children admitted with
unrousable coma and poor prognosis. It could be
deplored that several patients died because standard pro-
tocols used in western intensive care units were not avail-
able. This field reality did not preclude the value of the
demonstration of Epo high doses safety, the main objec-
tive of this study.
The comparison of case fatality rates with other cerebral
malaria studies in different settings are always controver-
sial. However, considering the severity of the disease at
admission and lack of standard supportive care for chil-
dren included in this study, the observed mortality rate of
20% could be analysed in the light of the case fatality rate
of 16.8% in Kenya [34]; 19,3% in SMAC network [35],
22% in Kenya [36]; 27% expected from five studies in
comparable endemic areas [26]. A recent study conducted
in the same ward showed a 16% case fatality rate for
patients admitted with cerebral malaria whatever the
coma score was [37]. Authors demonstrated that the low-
est the Blantyre score, the highest the mortality.Page 6 of 8
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Taken altogether, these data demonstrated that the short
term safety (seven days) of Epo high doses administered
during three days was obtained in children presenting
extremely severe cerebral malaria. Before these findings
can be considered as a clinical directive, the long-term
safety of Epo need to be further evaluated in larger-scale,
longer-term clinical studies. A randomized, double-
blinded, multi-centre trial will provide definitive informa-
tion on the potential of Epo as an adjunctive therapy in
humans and the effect of Epo plus anti-malarial drug
combination on CM case fatality rate [6]. The control of
apoptosis in brain during severe ischaemia-like injury
could be a new therapeutic opportunity in the future.
Here, in agreement with the Mali National Malaria Con-
trol Programme, cerebral malaria patients were treated
using quinine during the first three days. It is of interest to
test the beneficial effect of Epo combined with a more
potent ACT.
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